Giovanni Pascarella
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Giovanni Pascarella has a total of 160 co-authors. Here are the top co-authors by number of shared publications:
- Piero Carninci
RIKEN, Center for Integrative Medical Sciences
6 shared publications Martin Frith
Artificial Intelligence Research Center, National Institute of Advanced Industrial Science and Technology (AIST)
3 shared publications- Alessandra Sperotto
Veneto Institute of Oncology, Padua, Italy, Italy
2 shared publications - Alessandro Atanasio
Istituto Oncologico Veneto, Padua, Italy, Italy
2 shared publications - Federico De Marchi
Oncology-Veneto Institute of Oncology, Veneto Institute of Oncology, Padua, Italy, Italy
2 shared publications - Giulia Ciotti
UOSD Terapie Cellulari, Dipartimento di Oncologia, Istituto Oncologico Veneto (IOV), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), 35128 Padua, Italy
2 shared publications
Latest Publications
- Open Access
The human RNA-DNA interactome is cell type-specific and dynamic
More than twenty years ago, the FANTOM consortium uncovered that mammalian genomes are pervasively transcribed, revealing multitudes of RNAs with unknown functions. A subset of these transcripts has since then been linked to transcriptional control and to chromatin organization via their ability to interact with DNA, suggesting that chromatin-associated RNAs could be key players in genome regulation. Although recent technological advances now enable the mapping of genome-wide RNA-DNA contacts, a lack of analyses integrating these methods with other genomic features and across multiple cellular contexts hinders our comprehensive understanding of the principles underlying RNA-DNA interactions and of their biological importance. As part of the FANTOM6 project, we thus generated RNA-DNA interaction maps in 16 different human cell types, then combined these contacts with multiple layers of other genomic data to investigate how patterns of interaction between RNA and DNA relate to chromatin organization and function. We show that the RNA-DNA interactome is highly dynamic yet reproducibly organized in cell-type specific networks, constituted of a great diversity of interactions that vary in function of their distance, the nature of their sources and the chromatin state of their targets. In particular, we detected numerous regulatory elements that exhibit marked changes in activity when differentially bound by transcripts, implying that thousands of RNA-DNA interactions can play a mechanistic role in gene expression. This regulatory function correlates with RNA-protein interactions and significantly associates with cell type-relevant and disorder-related traits. In addition to providing essential resources for future research in RNA-mediated chromatin regulation, cellular biology and human diseases, our study thus establishes the RNA-DNA interactome as a new genome regulatory layer that defines and maintains cellular identity and behavior.
Open AccessThe human RNA-DNA interactome is cell type-specific and dynamic
More than twenty years ago, the FANTOM consortium uncovered that mammalian genomes are pervasively transcribed, revealing multitudes of RNAs with unknown functions. A subset of these transcripts has since then been linked to transcriptional control and to chromatin organization via their ability to interact with DNA, suggesting that chromatin-associated RNAs could be key players in genome regulation. Although recent technological advances now enable the mapping of genome-wide RNA-DNA contacts, a lack of analyses integrating these methods with other genomic features and across multiple cellular contexts hinders our comprehensive understanding of the principles underlying RNA-DNA interactions and of their biological importance. As part of the FANTOM6 project, we thus generated RNA-DNA interaction maps in 16 different human cell types, then combined these contacts with multiple layers of other genomic data to investigate how patterns of interaction between RNA and DNA relate to chromatin organization and function. We show that the RNA-DNA interactome is highly dynamic yet reproducibly organized in cell-type specific networks, constituted of a great diversity of interactions that vary in function of their distance, the nature of their sources and the chromatin state of their targets. In particular, we detected numerous regulatory elements that exhibit marked changes in activity when differentially bound by transcripts, implying that thousands of RNA-DNA interactions can play a mechanistic role in gene expression. This regulatory function correlates with RNA-protein interactions and significantly associates with cell type-relevant and disorder-related traits. In addition to providing essential resources for future research in RNA-mediated chromatin regulation, cellular biology and human diseases, our study thus establishes the RNA-DNA interactome as a new genome regulatory layer that defines and maintains cellular identity and behavior.
- Open Access
Putting the I in AML: Artificial Intelligence and Machine Learning in Acute Myeloid Leukemia
Artificial intelligence (AI) and machine learning (ML) now reach into every stage of AML care. Deep learning models read therapy-relevant mutations directly from bone marrow smears; automated flow cytometry gating reproduces expert calls in under a minute; and the first AI pathology devices for hematology have cleared regulatory review and entered clinical use. Beyond diagnosis, ML captures the age-dependent weight of individual mutations that categorical ELN scoring misses, drug response prediction for venetoclax–azacitidine has been validated across multiple external cohorts, and large language models are being tested for tumor board support and trial matching. The next wave, from clonal architecture modeling and single-cell foundation models to digital twins and reinforcement learning for adaptive dosing, could move AML management from reactive toward predictive, evolution-aware care. This review departs from existing AI-in-hematology surveys in three ways: we (i) restrict the scope to AML and organize the field around clinical decision points rather than technology categories, (ii) grade every tool on a five-tier author-defined clinical readiness level (CRL-AML 1–5), which exposes hundreds of models clustered at CRL-AML 1–2 and none yet in prospective clinical evaluation, and (iii) close with a numbered three-year agenda naming the consortia, datasets, and pragmatic trials needed to carry the field from publication to practice.
Open AccessPutting the I in AML: Artificial Intelligence and Machine Learning in Acute Myeloid Leukemia
Artificial intelligence (AI) and machine learning (ML) now reach into every stage of AML care. Deep learning models read therapy-relevant mutations directly from bone marrow smears; automated flow cytometry gating reproduces expert calls in under a minute; and the first AI pathology devices for hematology have cleared regulatory review and entered clinical use. Beyond diagnosis, ML captures the age-dependent weight of individual mutations that categorical ELN scoring misses, drug response prediction for venetoclax–azacitidine has been validated across multiple external cohorts, and large language models are being tested for tumor board support and trial matching. The next wave, from clonal architecture modeling and single-cell foundation models to digital twins and reinforcement learning for adaptive dosing, could move AML management from reactive toward predictive, evolution-aware care. This review departs from existing AI-in-hematology surveys in three ways: we (i) restrict the scope to AML and organize the field around clinical decision points rather than technology categories, (ii) grade every tool on a five-tier author-defined clinical readiness level (CRL-AML 1–5), which exposes hundreds of models clustered at CRL-AML 1–2 and none yet in prospective clinical evaluation, and (iii) close with a numbered three-year agenda naming the consortia, datasets, and pragmatic trials needed to carry the field from publication to practice.
- Open Access
- 5 August 2026
- Published by MDPI AG in Preprints.org
Putting the I in AML: Artificial Intelligence and Machine Learning in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) produces more molecular, imaging, and clinical data per patient than any hematologist can hold in mind at once, and each revision of the WHO, ICC, and European LeukemiaNet (ELN) frameworks adds to the load. Artificial intelligence (AI) and machine learning (ML) now reach into every stage of AML care. Deep-learning models read therapy-relevant mutations directly from bone-marrow smears; automated flow-cytometry gating reproduces expert calls in under a minute; and the first AI pathology devices for hematology have cleared regulatory review and entered clinical use. Beyond diagnosis, ML captures the age-dependent weight of individual mutations that categorical ELN scoring misses, drug-response prediction for venetoclax–azacitidine has been validated across multiple external cohorts, and large language models are being tested for tumor-board support and trial matching. The next wave, from clonal-architecture modeling and single-cell foundation models to digital twins and reinforcement learning for adaptive dosing, could move AML management from reactive toward predictive, evolution-aware care. This review departs from existing AI-in-hematology surveys in three ways: we (i) restrict scope to AML and organize the field around clinical decision points rather than technology categories, (ii) grade every tool on a five-tier clinical-readiness level (CRL-AML 1–5), which exposes hundreds of models clustered at CRL-AML 1–2 and none yet in prospective clinical evaluation, and (iii) close with a numbered three-year agenda naming the consortia, datasets, and pragmatic trials needed to carry the field from publication to practice.
- 5 August 2026
- Published by MDPI AG in Preprints.org
Open AccessPutting the I in AML: Artificial Intelligence and Machine Learning in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) produces more molecular, imaging, and clinical data per patient than any hematologist can hold in mind at once, and each revision of the WHO, ICC, and European LeukemiaNet (ELN) frameworks adds to the load. Artificial intelligence (AI) and machine learning (ML) now reach into every stage of AML care. Deep-learning models read therapy-relevant mutations directly from bone-marrow smears; automated flow-cytometry gating reproduces expert calls in under a minute; and the first AI pathology devices for hematology have cleared regulatory review and entered clinical use. Beyond diagnosis, ML captures the age-dependent weight of individual mutations that categorical ELN scoring misses, drug-response prediction for venetoclax–azacitidine has been validated across multiple external cohorts, and large language models are being tested for tumor-board support and trial matching. The next wave, from clonal-architecture modeling and single-cell foundation models to digital twins and reinforcement learning for adaptive dosing, could move AML management from reactive toward predictive, evolution-aware care. This review departs from existing AI-in-hematology surveys in three ways: we (i) restrict scope to AML and organize the field around clinical decision points rather than technology categories, (ii) grade every tool on a five-tier clinical-readiness level (CRL-AML 1–5), which exposes hundreds of models clustered at CRL-AML 1–2 and none yet in prospective clinical evaluation, and (iii) close with a numbered three-year agenda naming the consortia, datasets, and pragmatic trials needed to carry the field from publication to practice.
- Open Access
Ku limits aberrant mRNA splicing promoted by intronic antisense Alu elements
SUMMARY: Alu elements are short repeats that occupy approximately 10% of the human genome. The enrichment of primate genomes with Alu sequences occurred at the prosimian/new-world monkey evolutionary juncture, which coincided with a substantial increase in the expression levels of the Ku70/80 heterodimer. Previous work suggests that the elevated levels of Ku70/80 are required to prevent the activation of innate immune signaling pathways triggered by RNA molecules derived from Alu elements. Here we demonstrate that Ku regulates mRNA splicing, by inhibiting the use of alternative splice sites contained in intronic antisense Alu elements. Dysregulation of splicing precedes cell death and impacts genes involved in essential RNA metabolism processes, including splicing and ribosome biogenesis, likely impacting cell viability. We propose a model in which Ku binding of antisense Alu elements in introns of mRNAs modulates the use of alternative splice sites to balance beneficial and detrimental contributions of Alu repeats within primate genomes.
Open AccessKu limits aberrant mRNA splicing promoted by intronic antisense Alu elements
SUMMARY: Alu elements are short repeats that occupy approximately 10% of the human genome. The enrichment of primate genomes with Alu sequences occurred at the prosimian/new-world monkey evolutionary juncture, which coincided with a substantial increase in the expression levels of the Ku70/80 heterodimer. Previous work suggests that the elevated levels of Ku70/80 are required to prevent the activation of innate immune signaling pathways triggered by RNA molecules derived from Alu elements. Here we demonstrate that Ku regulates mRNA splicing, by inhibiting the use of alternative splice sites contained in intronic antisense Alu elements. Dysregulation of splicing precedes cell death and impacts genes involved in essential RNA metabolism processes, including splicing and ribosome biogenesis, likely impacting cell viability. We propose a model in which Ku binding of antisense Alu elements in introns of mRNAs modulates the use of alternative splice sites to balance beneficial and detrimental contributions of Alu repeats within primate genomes.
- Open Access
Challenges in Detecting Somatic Recombination of Repeat Elements: Insights from Short and Long Read Datasets
Non-allelic copies of the two major families of repeat elements in the human genome, Alu and L1, recombine somatically at high frequency. Tissue-specific recombination profiles are dynamic in cell differentiation and are altered in neurodegeneration, suggesting that somatic recombination of repeat elements can contribute to functional heterogeneity of cells in health and disease. The study of these genomic variants, however, presents several technical challenges related to their extremely low copy number and their sequence content. Here, we address key issues regarding detecting and annotating structural variants derived from recombining repeat elements in NGS data. We show that PCR introduces significant changes of recombination profiles in sequencing libraries and that recombination profiles are affected by the choice of sequencing platform. We refine previous estimates of recombination in single cells by analyzing recombination profiles in PCR-free HG002 datasets sequenced by Oxford Nanopore Technologies and PacBio sequencers while describing several platform-specific differences. We additionally provide evidence that recombination events annotated in state-of-the-art single-cell HG002 whole-genome sequencing datasets are likely molecular artifacts generated by PCR. By exploring the limits of current technologies, this work establishes essential requirements for future developments to enhance the reliability of detecting somatic recombination of repeat elements in genomic datasets.
Open AccessChallenges in Detecting Somatic Recombination of Repeat Elements: Insights from Short and Long Read Datasets
Non-allelic copies of the two major families of repeat elements in the human genome, Alu and L1, recombine somatically at high frequency. Tissue-specific recombination profiles are dynamic in cell differentiation and are altered in neurodegeneration, suggesting that somatic recombination of repeat elements can contribute to functional heterogeneity of cells in health and disease. The study of these genomic variants, however, presents several technical challenges related to their extremely low copy number and their sequence content. Here, we address key issues regarding detecting and annotating structural variants derived from recombining repeat elements in NGS data. We show that PCR introduces significant changes of recombination profiles in sequencing libraries and that recombination profiles are affected by the choice of sequencing platform. We refine previous estimates of recombination in single cells by analyzing recombination profiles in PCR-free HG002 datasets sequenced by Oxford Nanopore Technologies and PacBio sequencers while describing several platform-specific differences. We additionally provide evidence that recombination events annotated in state-of-the-art single-cell HG002 whole-genome sequencing datasets are likely molecular artifacts generated by PCR. By exploring the limits of current technologies, this work establishes essential requirements for future developments to enhance the reliability of detecting somatic recombination of repeat elements in genomic datasets.
- Open Access
- 20 March 2023
- Published by Wiley in Clinical and Translational Medicine
- Vol. 13 (3) , e1226
A new layer of complexity in the human genome: Somatic recombination of repeat elements
- 20 March 2023
- Published by Wiley in Clinical and Translational Medicine
- Vol. 13 (3) , e1226
Open AccessA new layer of complexity in the human genome: Somatic recombination of repeat elements
- Open Access
- 14 January 2023
- Published by Elsevier in STAR Protocols
- Vol. 4 (1)
Capture-seq protocol and TE-reX pipeline guidelines for detection of recombination of repeat elements in short- and long-DNA reads libraries
- 14 January 2023
- Published by Elsevier in STAR Protocols
- Vol. 4 (1)
Open AccessCapture-seq protocol and TE-reX pipeline guidelines for detection of recombination of repeat elements in short- and long-DNA reads libraries